Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease.
Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease.
复制标题
DOI：
10.1586/14760584.3.6.693
复制
发表时间：
2004-12-01
影响因子：
6.2
通讯作者：
Polack, Fernando P
中科院分区：
文献类型：
--
作者：
Delgado, M Florencia;Polack, Fernando P
1966年，美国的婴儿和儿童接种了针对呼吸道合胞病毒的福尔马林灭活疫苗。该疫苗具有免疫原性，但主要引起非保护性抗体。在社区接触呼吸道合胞病毒后，接种疫苗的儿童出现了以支气管收缩和肺炎为特征的严重肺部疾病。两名接种疫苗的婴儿在蹒跚学步时死于呼吸道合胞病毒感染。几十年来，对疾病机制的探索一直主导着文献。本文综述了呼吸道合胞病毒疫苗的研究进展，并对增强型呼吸道疾病的发病机制进行了讨论。
In 1966, infants and children in the USA were immunized with a formalin-inactivated vaccine against respiratory syncytial virus. The vaccine was immunogenic but elicited mainly nonprotective antibody. Upon exposure to respiratory syncytial virus in the community, immunized children developed severe pulmonary disease characterized by bronchoconstriction and pneumonia. Two immunized infants died as toddlers after respiratory syncytial virus infection. Exploration of the mechanisms of disease has dominated the literature for decades. In this review, the pathogenesis of enhanced respiratory disease is discussed and the characteristics of protective and pathogenic respiratory syncytial virus vaccines are examined.